chlorzoxazone Side Effects
Also known as: Parafon Forte
Analysis of 1,256 adverse event reports submitted to the FDA from 2004 to 2025.
Total Reports
1,256
Death-Related
130
10.4% of reports
Hospitalizations
346
27.5% of reports
Top Indication
Product Used For Unknown Indication
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 130 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| COMPLETED SUICIDE | 43 |
| TOXICITY TO VARIOUS AGENTS | 18 |
| DEATH | 16 |
| STEVENS-JOHNSON SYNDROME | 14 |
| CARDIO-RESPIRATORY ARREST | 9 |
| CHRONIC KIDNEY DISEASE | 7 |
| CIRCULATORY COLLAPSE | 7 |
| DEPRESSED LEVEL OF CONSCIOUSNESS | 7 |
| DIZZINESS | 7 |
| RESPIRATORY ARREST | 7 |
| RESPIRATORY DEPRESSION | 7 |
| ACUTE KIDNEY INJURY | 6 |
| HEPATOTOXICITY | 6 |
| RENAL FAILURE | 6 |
| COMA | 5 |
| MULTIPLE DRUG OVERDOSE | 5 |
| OVERDOSE | 5 |
| CARDIAC ARREST | 4 |
| HEART RATE INCREASED | 4 |
| STUPOR | 4 |
Reactions in Hospitalization Reports
Top reactions in 346 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| PAIN | 36 |
| PNEUMONIA | 30 |
| ANXIETY | 29 |
| NAUSEA | 27 |
| FATIGUE | 25 |
| DYSPNOEA | 23 |
| TOXICITY TO VARIOUS AGENTS | 23 |
| FALL | 21 |
| ACUTE KIDNEY INJURY | 20 |
| CHEST PAIN | 15 |
| DEPRESSION | 15 |
| EMOTIONAL DISTRESS | 15 |
| VOMITING | 15 |
| CHRONIC KIDNEY DISEASE | 14 |
| DIZZINESS | 14 |
| INTENTIONAL OVERDOSE | 14 |
| SUICIDE ATTEMPT | 14 |
| DIARRHOEA | 13 |
| LOSS OF CONSCIOUSNESS | 13 |
| ABDOMINAL PAIN | 12 |
Nearby — Related Medications
What the FAERS Data Reveals About chlorzoxazone Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 1,256 voluntary reports linked to chlorzoxazone and its brand equivalents (Parafon Forte), spanning 2004 through 2025. Of those, 130 (10.4%) listed death as an outcome and 346 (27.5%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 75% were female and 25% male; age distribution skews toward 45-64, with 417 reports in that bracket. The single most reported reaction is dizziness with 94 submissions, followed by nausea and fatigue.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.